Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 4/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20101964 | 0.79 | LMNA (0.44) | LMNAMAPK1RAB9AGPR119ERN1 | |
| SCHEMBL4195614 | 0.76 | LMNA (0.46) | LMNAMAPK1RAB9AGPR119ERN1 | |
| SCHEMBL9381596 | 0.75 | LMNA (0.39) | LMNAMAPK1RAB9AGPR119ERN1 | |
| SCHEMBL3997516 | 0.74 | LMNA (0.45) | LMNAMAPK1RAB9AGPR119ERN1 | |
| SCHEMBL3992214 | 0.74 | LMNA (0.45) | LMNAMAPK1RAB9AGPR119ERN1 | |
| SCHEMBL30736650 | 0.74 | CYP1A2 (0.43) | LMNAMAPK1RAB9A | |
| SCHEMBL30854400 | 0.73 | LMNA (0.40) | LMNAMAPK1RAB9AGPR119ERN1 | |
| SCHEMBL31097155 | 0.73 | TPSAB1 (0.47) | LMNAMAPK1RAB9AGPR119L3MBTL1 | |
| SCHEMBL31097156 | 0.73 | TPSAB1 (0.47) | LMNAMAPK1RAB9AGPR119L3MBTL1 | |
| Hydrochloric Acid SCHEMBL30984509 | 0.73 | CYP1A2 (0.42) | LMNAMAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202246-B2 | Spiro-rifamycin derivatives targeting RNA polymerase | CUMBRE PHARMACEUTICALS INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050277633-A1 | E.g., rifamycin S derivatives such as 2',2'-Dimethyl-3,4-piperazinorifamycin S and Spiro[N-methyl-piperidine-3,4-piperazinorifamycin S; treating bacterial infections, especially those caused by rifamycin-resistant bacteria | CUMBRE INC. (US) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277633-A1 | E.g., rifamycin S derivatives such as 2',2'-Dimethyl-3,4-piperazinorifamycin S and Spiro[N-methyl-piperidine-3,4-piperazinorifamycin S; treating bacterial infections, especially those caused by rifamycin-resistant bacteria | RIF1, MAPRE1, MAPRE2 | LMNA 1920/4885MAPK1 2161/4885RAB9A 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.